Management of delirium in adult critically ill patients: An overview

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 15, Issue 4, 2012, Pages 499-509

  Banh, Hoan Linh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLONIDINE; DEXMEDETOMIDINE; HALOPERIDOL; LORAZEPAM; MELATONIN; MIDAZOLAM; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; ZIPRASIDONE;

AKATHISIA; ALTERNATIVE MEDICINE; ALZHEIMER DISEASE; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DELIRIUM; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; HEART ARRHYTHMIA; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; MASSAGE; MUSIC THERAPY; NOISE REDUCTION; PARADOXICAL DRUG REACTION; PARKINSON DISEASE; PARKINSONISM; PATIENT ASSESSMENT; PSYCHIATRIC TREATMENT; QT PROLONGATION; RELAXATION TRAINING; REVIEW; RISK FACTOR; SEDATION; SEIZURE; SIDE EFFECT; SLEEP THERAPY; SOMNOLENCE; STOMACH PARESIS; TACHYCARDIA; TREATMENT INDICATION;

EID: 84865847289     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/J3PK69     Document Type: Review

References (115)

1. Bergeron N, Skrobik Y, Dubois MJ. Delirium in critically ill patients. Crit Care. 2002 Jun;6(3):181-2.
2. Lacasse H, Perreault MM, Williamson DR. Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. Ann Pharmacother. 2006 Nov;40(11):1966-73.
3. Jaber S, Chanques G, Altairac C, Sebbane M, Vergne C, Perrigault PF, et al. A prospective study of agitation in a medical-surgical ICU: Incidence, risk factors, and outcomes. Chest. 2005 Oct;128(4):2749-57.
4. Ouimet S, Kavanagh BP, Gottfried SB, Skrobik Y. Incidence, risk factors and consequences of ICU delirium. Intensive Care Med. 2007 Jan;33(1):66-73.
5. Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002 Jan;30(1):119-41.
6. Trzepacz PT. Update on the neuropathogenesis of delirium. Dement Geriatr Cogn Disord. 1999 Sep-Oct;10(5):330-4.
7. Gaudreau JD, Gagnon P. Psychotogenic drugs and delirium pathogenesis: The central role of the thalamus. Med Hypotheses. 2005;64(3):471-5.
8. Flacker JM, Cummings V, Mach JR, Jr, Bettin K, Kiely DK, Wei J. The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry. 1998 Winter;6(1):31-41.
9. Trzepacz PT. Delirium. advances in diagnosis, pathophysiology, and treatment. Psychiatr Clin North Am. 1996 Sep;19(3):429-48.
10. van Gool WA, van de Beek D, Eikelenboom P. Systemic infection and delirium: When cytokines and acetylcholine collide. Lancet. 2010 Feb 27;375(9716):773-5.
11. Reynolds GP. Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol. 2004 Sep;18(3):340-5.
12. Trzepacz PT. The neuropathogenesis of delirium. A need to focus our research. Psychosomatics. 1994 Jul-Aug;35(4):374-91.
13. Dubois MJ, Bergeron N, Dumont M, Dial S, Skrobik Y. Delirium in an intensive care unit: A study of risk factors. Intensive Care Med. 2001 Aug;27(8):1297-304.
14. Aldemir M, Ozen S, Kara IH, Sir A, Bac B. Predisposing factors for delirium in the surgical intensive care unit. Crit Care. 2001 Oct;5(5):265-70.
15. Milbrandt EB, Deppen S, Harrison PL, Shintani AK, Speroff T, Stiles RA, et al. Costs associated with delirium in mechanically ventilated patients. Crit Care Med. 2004 Apr;32(4):955-62.
16. Pandharipande P, Shintani A, Peterson J, Pun BT, Wilkinson GR, Dittus RS, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology. 2006 Jan;104(1):21-6.
17. Plaschke K, von Haken R, Scholz M, Engelhardt R, Brobeil A, Martin E, et al. Comparison of the confusion assessment method for the intensive care unit (CAM-ICU) with the intensive care delirium screening checklist (ICDSC) for delirium in critical care patients gives high agreement rate(s). Intensive Care Med. 2008 Mar;34(3):431-6.
18. Devlin JW, Fong JJ, Schumaker G, O'Connor H, Ruthazer R, Garpestad E. Use of a validated delirium assessment tool improves the ability of physicians to identify delirium in medical intensive care unit patients. Crit Care Med. 2007 Dec;35(12):2721,4; quiz 2725.
19. Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE, Jr, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004 Apr 14;291(14):1753-62.
20. Inouye SK, Baker DI, Fugal P, Bradley EH, for the HELP Dissemination Project. Dissemination of the hospital elder life program: Implementation, adaptation, and successes. J Am Geriatr Soc. 2006 Oct;54(10):1492-9.
21. Lundstrom M, Edlund A, Karlsson S, Brannstrom B, Bucht G, Gustafson Y. A multifactorial intervention program reduces the duration of delirium, length of hospitalization, and mortality in delirious patients. J Am Geriatr Soc. 2005 Apr;53(4):622-8.
22. Marcantonio ER, Flacker JM, Wright RJ, Resnick NM. Reducing delirium after hip fracture: A randomized trial. J Am Geriatr Soc. 2001 May;49(5):516-22.
23. Milisen K, Foreman MD, Abraham IL, De Geest S, Godderis J, Vandermeulen E, et al. A nurse-led interdisciplinary intervention program for delirium in elderly hip-fracture patients. J Am Geriatr Soc. 2001 May;49(5):523-32.
24. Morrison RS, Magaziner J, Gilbert M, Koval KJ, McLaughlin MA, Orosz G, et al. Relationship between pain and opioid analgesics on the development of delirium following hip fracture. J Gerontol A Biol Sci Med Sci. 2003 Jan;58(1):76-81.
25. Kress JP, Pohlman AS, Hall JB. Sedation and analgesia in the intensive care unit. Am J Respir Crit Care Med. 2002 Oct 15;166(8):1024-8.
26. Carson SS, Kress JP, Rodgers JE, Vinayak A, Campbell-Bright S, Levitt J, et al. A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Crit Care Med. 2006 May;34(5):1326-32.
27. Kress JP, Gehlbach B, Lacy M, Pliskin N, Pohlman AS, Hall JB. The long-term psychological effects of daily sedative interruption on critically ill patients. Am J Respir Crit Care Med. 2003 Dec 15;168(12):1457-61.
28. Berry E, Zecca H. Daily interruptions of sedation: A clinical approach to improve outcomes in critically ill patients. Crit Care Nurse. 2012 Feb;32(1):43-51.
29. Dotson B. Daily interruption of sedation in patients treated with mechanical ventilation. Am J Health Syst Pharm. 2010 Jun 15;67(12):1002-6.
30. Inouye SK, Bogardus ST, Jr, Charpentier PA, Leo-Summers L, Acampora D, Holford TR, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999 Mar 4;340(9):669-76.
31. Inouye SK. Predisposing and precipitating factors for delirium in hospitalized older patients. Dement Geriatr Cogn Disord. 1999 Sep-Oct;10(5):393-400.
32. Inouye SK, Bogardus ST, Jr, Williams CS, Leo-Summers L, Agostini JV. The role of adherence on the effectiveness of nonpharmacologic interventions: Evidence from the delirium prevention trial. Arch Intern Med. 2003 Apr 28;163(8):958-64.
33. Siddiqi N, Stockdale R, Britton AM, Holmes J. Interventions for preventing delirium in hospitalised patients. Cochrane Database Syst Rev. 2007 Apr 18;(2)(2):CD005563.
34. Hofhuis JG, Spronk PE, van Stel HF, Schrijvers AJ, Rommes JH, Bakker J. Experiences of critically ill patients in the ICU. Intensive Crit Care Nurs. 2008 Oct;24(5):300-13.
35. Busch-Vishniac IJ, West JE, Barnhill C, Hunter T, Orellana D, Chivukula R. Noise levels in johns hopkins hospital. J Acoust Soc Am. 2005 Dec;118(6):3629-45.
36. Guidelines for community noise. [Internet]. Available from: http://whqlibdoc.who.int/hq/1999/a68672.pdf.
37. Scotto CJ, McClusky C, Spillan S, Kimmel J. Earplugs improve patients' subjective experience of sleep in critical care. Nurs Crit Care. 2009 Jul-Aug;14(4):180-4.
38. Hipp DM, Ely EW. Pharmacological and nonpharmacological management of delirium in critically ill patients. Neurotherapeutics. 2012 Jan;9(1):158-75.
39. Girard TD, Pandharipande PP, Ely EW. Delirium in the intensive care unit. Crit Care. 2008;12 Suppl 3:S3.
40. Kapur S, Remington G, Jones C, Wilson A, Da Silva J, Houle S, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: A PET study. Am J Psychiatry. 1996 Jul;153(7):948-50.
41. Wolkin A, Brodie JD, Barouche F, Rotrosen J, Wolf AP, Smith M, et al. Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry. 1989 May;46(5):482-4.
42. Jones SF, Pisani MA. ICU delirium: An update. Curr Opin Crit Care. 2012 Apr;18(2):146-51.
43. Practice guideline for the treatment of patients with delirium. american psychiatric association. Am J Psychiatry. 1999 May;156(5 Suppl):1-20.
44. The management of the agitated ICU patient. Crit Care Med. 2002 Jan;30(1 Suppl Management):S97,123; quiz S124-25.
45. Riker RR, Fraser GL, Cox PM. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med. 1994 Mar;22(3):433-40.
46. Seneff MG, Mathews RA. Use of haloperidol infusions to control delirium in critically ill adults. Ann Pharmacother. 1995 Jul-Aug;29(7-8):690-3.
47. Trujillo MH, Bellorin-Font E. Drugs commonly administered by intravenous infusion in intensive care units: A practical guide. Crit Care Med. 1990 Feb;18(2):232-8.
48. Rea RS, Battistone S, Fong JJ, Devlin JW. Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients. Pharmacotherapy. 2007 Apr;27(4):588-94.
49. Skrobik Y. Haloperidol should be used sparingly. Crit Care Med. 2002 Nov;30(11):2613,4; author reply 2614.
50. Pisani MA, Murphy TE, Araujo KL, Slattum P, Van Ness PH, Inouye SK. Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. Crit Care Med. 2009 Jan;37(1):177-83.
51. Breitbart W, Marotta R, Platt MM, Weisman H, Derevenco M, Grau C, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry. 1996 Feb;153(2):231-7.
52. Mayo-Smith MF, Beecher LH, Fischer TL, Gorelick DA, Guillaume JL, Hill A, et al. Management of alcohol withdrawal delirium. an evidence-based practice guideline. Arch Intern Med. 2004 Jul 12;164(13):1405-12.
53. Altar CA, Wasley AM, Neale RF, Stone GA. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: An autoradiographic analysis in rat brain. Brain Res Bull. 1986 Apr;16(4):517-25.
54. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989 Oct;251(1):238-46.
55. Rasmussen K, Aghajanian GK. Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity. Neuropsychopharmacology. 1988 May;1(2):101-7.
56. Baldessarini RJ TF. Drugs and the treatment of psychiatric disorders. In: Hardman JG LL, editor. Goodman & Gilman's The Pharmacological Basics of Therapeutics.; 2001. p. 485-520.
57. Trichard C, Paillere-Martinot ML, Attar-Levy D, Recassens C, Monnet F, Martinot JL. Binding of antipsychotic drugs to cortical 5-HT2A receptors: A PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry. 1998 Apr;155(4):505-8.
58. Gilchrist NA, Asoh I, Greenberg B. Analytic reviews: Atypical antipsychotics for the treatment of ICU delirium. J Intensive Care Med. 2011 Mar 25.
59. Miller DD. Atypical antipsychotics: Sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry. 2004;6(Suppl 2):3-7.
60. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002;16(1):23-45.
61. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: Differential risk and clinical implications. CNS Drugs. 2007;21(11):911-36.
62. Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, et al. Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophr Res. 2009 Jun;111(1-3):9-16.
63. Stahl S. Describing an antipsychotic: Receptor binding and its role in pathophysiology. Primary care companion to the Journal of clinical psychiatry. 2003;5(suppl 3):9-13.
64. Karan R, Pandhi P. D2 and 5HT2 receptors: Relevance to antipsychotic drugs. Indian Journal of Pharmacology. 2000;32:187-91.
65. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. part I: Pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother. 1999 Jan;33(1):73-85.
66. Brown CS, Markowitz JS, Moore TR, Parker NG. Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs. Ann Pharmacother. 1999 Feb;33(2):210-7.
67. Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: Treating delirium in a critical care setting. Intensive Care Med. 2004 Mar;30(3):444-9.
68. Devlin JW, Roberts RJ, Fong JJ, Skrobik Y, Riker RR, Hill NS, et al. Efficacy and safety of quetiapine in critically ill patients with delirium: A prospective, multicenter, randomized, double-blind, placebocontrolled pilot study. Crit Care Med. 2010 Feb;38(2):419-27.
69. Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics. 2004 Jul-Aug;45(4):297-301.
70. Tavcar R, Dernovsek MZ. Risperidone-induced delirium. Can J Psychiatry. 1998 Mar;43(2):194.
71. Ravona-Springer R, Dolberg OT, Hirschmann S, Grunhaus L. Delirium in elderly patients treated with risperidone: A report of three cases. J Clin Psychopharmacol. 1998 Apr;18(2):171-2.
72. Goodnick PJ. Ziprasidone: Profile on safety. Expert Opin Pharmacother. 2001 Oct;2(10):1655-62.
73. Girard TD, Pandharipande PP, Carson SS, Schmidt GA, Wright PE, Canonico AE, et al. Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: The MIND randomized, placebocontrolled trial. Crit Care Med. 2010 Feb;38(2):428-37.
74. Gerlach AT, Murphy CV, Dasta JF. An updated focused review of dexmedetomidine in adults. Ann Pharmacother. 2009 Dec;43(12):2064-74.
75. Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: The MENDS randomized controlled trial. JAMA. 2007 Dec 12;298(22):2644-53.
76. Lachaine J, Beauchemin C. Economic evaluation of dexmedetomidine relative to midazolam for sedation in the intensive care unit. Can J Hosp Pharm. 2012 Mar;65(2):103-10.
77. Ruokonen E, Parviainen I, Jakob SM, Nunes S, Kaukonen M, Shepherd ST, et al. Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation. Intensive Care Med. 2009 Feb;35(2):282-90.
78. O'brien C. Drug addictions and drug abuse. In: Hardman JG LL, editor. Goodman & Gilman's The Pharmacological Basis of Therapeutics.; 2001. p. 621-42.
79. Bond WS. Psychiatric indications for clonidine: The neuropharmacologic and clinical basis. J Clin Psychopharmacol. 1986 Apr;6(2):81-7.
80. Glassman AH, Stetner F, Walsh BT, Raizman PS, Fleiss JL, Cooper TB, et al. Heavy smokers, smoking cessation, and clonidine. results of a double-blind, randomized trial. JAMA. 1988 May 20;259(19):2863-6.
81. Gold MS, Redmond DE, Jr, Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. Lancet. 1978 Sep 16;2(8090):599-602.
82. Rubino AS, Onorati F, Caroleo S, Galato E, Nucera S, Amantea B, et al. Impact of clonidine administration on delirium and related respiratory weaning after surgical correction of acute type-A aortic dissection: Results of a pilot study. Interact Cardiovasc Thorac Surg. 2010 Jan;10(1):58-62.
83. Golinger RC, Peet T, Tune LE. Association of elevated plasma anticholinergic activity with delirium in surgical patients. Am J Psychiatry. 1987 Sep;144(9):1218-20.
84. Overshott R, Karim S, Burns A. Cholinesterase inhibitors for delirium. Cochrane Database Syst Rev. 2008 Jan 23;(1)(1):CD005317.
85. Overshott R, Vernon M, Morris J, Burns A. Rivastigmine in the treatment of delirium in older people: A pilot study. Int Psychogeriatr. 2010 Aug;22(5):812-8.
86. Oldenbeuving AW, de Kort PL, Jansen BP, Kappelle LJ, Roks G. A pilot study of rivastigmine in the treatment of delirium after stroke: A safe alternative. BMC Neurol. 2008 Sep 20;8:34.
87. Fischer P. Successful treatment of nonanticholinergic delirium with a cholinesterase inhibitor. J Clin Psychopharmacol. 2001 Feb;21(1):118.
88. van Eijk MM, Roes KC, Honing ML, Kuiper MA, Karakus A, van der Jagt M, et al. Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: A multicentre, double-blind, placebo-controlled randomised trial. Lancet. 2010 Nov 27;376(9755):1829-37.
89. National institutes of health. what is complementary and alternative medicine? [online] july 2011 [cited 2011 oct 10]. available from: Http://nccam.nih.gov/health/whatiscam/#definingca m [Internet].
90. Natural health products directorate. baseline natural health products survey among consumers: Final report. natural health products directorate; 2005.
91. Cooke M, Mitchell M, Tiralongo E, Murfield J. Complementary and alternative medicine and critical care nurses: A survey of knowledge and practices in australia. Aust Crit Care. 2012 Jan 25.
92. Tracy MF, Lindquist R, Savik K, Watanuki S, Sendelbach S, Kreitzer MJ, et al. Use of complementary and alternative therapies: A national survey of critical care nurses. Am J Crit Care. 2005 Sep;14(5):404,14; quiz 415-16.
93. Lindquist R, Tracy MF, Savik K. Personal use of complementary and alternative therapies by critical care nurses. Crit Care Nurs Clin North Am. 2003 Sep;15(3):393,9, x.
94. Lindquist R, Tracy MF, Savik K, Watanuki S. Regional use of complementary and alternative therapies by critical care nurses. Crit Care Nurse. 2005 Apr;25(2):63,4, 66-8, 70-2 passim.
95. Tracy MF, Lindquist R, Watanuki S, Sendelbach S, Kreitzer MJ, Berman B, et al. Nurse attitudes towards the use of complementary and alternative therapies in critical care. Heart Lung. 2003 May-Jun;32(3):197-209.
96. Dijkstra BM, Gamel C, van der Bijl JJ, Bots ML, Kesecioglu J. The effects of music on physiological responses and sedation scores in sedated, mechanically ventilated patients. J Clin Nurs. 2010 Apr;19(7-8):1030-9.
97. Chlan L. Effectiveness of a music therapy intervention on relaxation and anxiety for patients receiving ventilatory assistance. Heart Lung. 1998 May-Jun;27(3):169-76.
98. Chlan LL. Psychophysiologic responses of mechanically ventilated patients to music: A pilot study. Am J Crit Care. 1995 May;4(3):233-8.
99. Wong HL, Lopez-Nahas V, Molassiotis A. Effects of music therapy on anxiety in ventilator-dependent patients. Heart Lung. 2001 Sep-Oct;30(5):376-87.
100. Krachman SL, D'Alonzo GE, Criner GJ. Sleep in the intensive care unit. Chest. 1995 Jun;107(6):1713-20.
101. Yildizeli B, Ozyurtkan MO, Batirel HF, Kuscu K, Bekiroglu N, Yuksel M. Factors associated with postoperative delirium after thoracic surgery. Ann Thorac Surg. 2005 Mar;79(3):1004-9.
102. Olson DM, Borel CO, Laskowitz DT, Moore DT, McConnell ES. Quiet time: A nursing intervention to promote sleep in neurocritical care units. Am J Crit Care. 2001 Mar;10(2):74-8.
103. Richards KC. Effect of a back massage and relaxation intervention on sleep in critically ill patients. Am J Crit Care. 1998 Jul;7(4):288-99.
104. Richards KC, Gibson R, Overton-McCoy AL. Effects of massage in acute and critical care. AACN Clin Issues. 2000 Feb;11(1):77-96.
105. Brzezinski A. Melatonin in humans. N Engl J Med. 1997 Jan 16;336(3):186-95.
106. Gupta N, de Jonghe J, Schieveld J, Leonard M, Meagher D. Delirium phenomenology: What can we learn from the symptoms of delirium? J Psychosom Res. 2008 Sep;65(3):215-22.
107. Lewis MC, Barnett SR. Postoperative delirium: The tryptophan dyregulation model. Med Hypotheses. 2004;63(3):402-6.
108. Magri F, Sarra S, Cinchetti W, Guazzoni V, Fioravanti M, Cravello L, et al. Qualitative and quantitative changes of melatonin levels in physiological and pathological aging and in centenarians. J Pineal Res. 2004 May;36(4):256-61.
109. Haimov I, Laudon M, Zisapel N, Souroujon M, Nof D, Shlitner A, et al. Sleep disorders and melatonin rhythms in elderly people. BMJ. 1994 Jul 16;309(6948):167.
110. Balan S, Leibovitz A, Zila SO, Ruth M, Chana W, Yassica B, et al. The relation between the clinical subtypes of delirium and the urinary level of 6-SMT. J Neuropsychiatry Clin Neurosci. 2003 Summer;15(3):363-6.
111. Shigeta H, Yasui A, Nimura Y, Machida N, Kageyama M, Miura M, et al. Postoperative delirium and melatonin levels in elderly patients. Am J Surg. 2001 Nov;182(5):449-54.
112. Ibrahim MG, Bellomo R, Hart GK, Norman TR, Goldsmith D, Bates S, et al. A double-blind placebocontrolled randomised pilot study of nocturnal melatonin in tracheostomised patients. Crit Care Resusc. 2006 Sep;8(3):187-91.
113. Bourne RS, Mills GH, Minelli C. Melatonin therapy to improve nocturnal sleep in critically ill patients: Encouraging results from a small randomised controlled trial. Crit Care. 2008;12(2):R52.
114. Shilo L, Dagan Y, Smorjik Y, Weinberg U, Dolev S, Komptel B, et al. Effect of melatonin on sleep quality of COPD intensive care patients: A pilot study. Chronobiol Int. 2000 Jan;17(1):71-6.
115. van den Boogaard M, Schoonhoven L, Evers AW, van der Hoeven JG, van Achterberg T, Pickkers P. Delirium in critically ill patients: Impact on longterm health-related quality of life and cognitive functioning. Crit Care Med. 2012 Jan;40(1):112-8.